One of the first studies to evaluate IBD patients with a history of cancer who were exposed to both antimetabolites (thiopurines, methotrexate) and anti-TNF therapy demonstrated that immunosuppressive treatment following a cancer diagnosis was not associated with an increased risk of either new or recurrent malignancy. This evidence concerns the gene TNF and inflammatory bowel disease.